Brief: Gensight Biologics: 1 Year Safety Data And Efficacy Signals From Phase I/Ii Trial Of GS030

Gensight Biologics SA

13/02/2023 06:32

Feb 13 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS ANNOUNCES 1 YEAR SAFETY DATA AND
EFFICACY
SIGNALS FROM PIONEER PHASE I/II CLINICAL TRIAL OF GS030, AN
OPTOGENETIC TREATMENT CANDIDATE FOR RETINITIS PIGMENTOSA
    * GENSIGHT BIOLOGICS SA - GS030 IS SAFE AND WELL TOLERATED
FOR AT
LEAST 1 YEAR AFTER INJECTION AT ALL TESTED DOSES
    * GENSIGHT BIOLOGICS SA - ENCOURAGING EFFICACY SIGNALS
OBSERVED IN
SOME PATIENTS
    * GENSIGHT BIOLOGICS SA - ONGOING RECRUITMENT OF GS030
EXTENSION
COHORT AT HIGHEST DOSE OF 5E11 VG PER EYE

Source text for Eikon:  ID:nBw9vHVLda 
Further company coverage:  SIGHT.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))